Anzeige
Mehr »
Freitag, 18.09.2026 - Börsentäglich über 12.000 News
Gallium - Das Metall hinter dem KI-Boom
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
227 Leser
Artikel bewerten:
(1)

Her Case Matters on Hair Relaxer Lawsuits: What You Need to Know in 2026

For decades, women trusted chemical hair straighteners and relaxers to help them change their looks. However, in the present day, it's believed that using these hair relaxer products could lead to a higher risk of cancer.

BOSTON, MA / ACCESS Newswire / September 18, 2026 / A recent report from the National Institutes of Health (NIH) found that women who used hair straighteners or relaxers 4 times or more within a 1-year span were twice as likely to develop uterine cancer. 60% of those who used such products were Black women.

Now, women who relied on hair relaxers and straighteners are taking action through lawsuits to pursue justice for what happened.

Over 10,000 claims have been filed in a type of collective product liability lawsuit known as a multidistrict litigation (MDL) by women who allege their cancer diagnoses stem from the use of these products.

Her Case Matters, a national resource dedicated to supporting women who were harmed unfairly, is monitoring the latest chemical hair straightener litigation closely to help those affected make more informed choices.

Understanding this litigation requires understanding why chemical hair relaxers became so popular among women of color. Hair straightening was not simply a cosmetic preference - for many Black women, it was a response to discrimination.

Historically, up to 95% of adult Black women have used hair relaxers at some point. A recent Michigan State University study found that 80% of Black women felt the need to straighten their hair to fit in at work, with 66% reporting they felt obligated to straighten their hair before a job interview.

The companies that manufactured, marketed, and profited from that pressure may have known that the chemicals in hair straighteners could cause harm. Ongoing lawsuits seek to right these wrongs.

Chemical hair straightener litigation centers on a landmark 2022 study from the NIH, where it was found that women who frequently used hair straighteners were more than twice as likely to develop uterine cancer as those who did not. Around 6 out of 10 study participants were Black women.

The NIH study was not an isolated finding. A follow-up study published in Environmental Research found that long-term use of chemical hair relaxers was associated with higher odds of uterine cancer, with women using relaxers for 20 or more years showing a 71% higher risk compared to those who didn't use them.

Earlier studies from the same cohort had also connected hair relaxers to uterine fibroids, a condition estimated to affect 80% of Black women over their lifetime, as well as to links with breast cancer, ovarian cancer, and earlier onset of puberty in girls.

It's believed that hair relaxers may contain toxic substances, including formaldehyde, parabens, phthalates, bisphenol A, metals, and sodium hydroxide. These can mimic or amplify estrogen in the body, disrupting normal hormones and increasing the odds of cancer.

The hair relaxer MDL was established in February 2023 in the Northern District of Illinois. As of July 2026, there are 11,877 plaintiffs in the federal hair relaxer MDL, in addition to cases pending in state courts in Illinois, Georgia, Pennsylvania, New York, and elsewhere.

The litigation is currently the fourth-largest active mass tort in the United States. The defendants named include high-profile beauty companies that may have allegedly marketed hair straighteners to Black and Brown women while failing to warn about the risks.

No global settlement has been reached, and no plaintiff has received a settlement payout through the federal MDL just yet. The first trials are slated for 2027.

If you or a woman you love used chemical hair straighteners or relaxers and is now sick with uterine or ovarian cancer, you may be eligible to file a claim.

Her Case Matters is committed to supporting women whose lives were changed by chemical hair-related cancers. Visit the Her Case Matters website to learn more about your legal options, including how to get a free case review, when to file a claim if eligible, and more.

About Her Case Matters: Her Case Matters is a legal advocacy resource dedicated exclusively to women survivors of pharmaceutical harm, corporate negligence, sexual violence, and medical misconduct. The organization provides compassionate, expert guidance on civil legal options and connects women with experienced attorneys committed to accountability and full compensation.

CONTACT:

Her Case Matters
1330 Boylston St., Suite #400
Chestnut Hill, MA 02467
(855) 346-6101
wecanhelp@hercasematters.com

SOURCE: Her Case Matters



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/publishing-and-media/her-case-matters-on-hair-relaxer-lawsuits-what-you-need-to-know-in-2026-1223979

© 2026 ACCESS Newswire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.